---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Special populations"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Special populations. Topics: Older adults: exposure in elderly compared with young healthy participants, Chinese adults: bridging study and ethnic differences, Japanese adults: phase 1 study results, Renal impairment: minor urinary excretion, and 14 further topics. 18 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/special-populations"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Older adults: exposure in elderly compared with young healthy participants

> “There were a 22% increase in Cmax and 39% increase in AUC of lanifibranor in elderly subjects as compared to young subjects.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Single ascending doses (SAD) of oral lanifibranor were administered to 7 groups of young healthy male participants and 1 group of elderly healthy male and female participants following an interval of at least 6 days between dose levels to ensure safety and tolerability”
> “Aged 60-80 years inclusive.”

Source: [Francque et al. (2026)](https://inventivapharma.com/wp-content/uploads/MASH-2026-Clinical-PK-PD-poster_LUM-03426_v2.pdf)

<a id="topic-2.1.2.8-2"></a>

### Chinese adults: bridging study and ethnic differences

> “Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial.”

Source: [Inventiva CTTQ milestone release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-CTTQ-milestone-EN-07-07-2025.pdf)

<a id="topic-2.1.2.8-3"></a>

### Japanese adults: phase 1 study results

> “In 2025, Hepalys conducted a Phase 1 trial of lanifibranor in Japan. The results of this Phase 1 trial were positive and are expected to support the initiation of a dedicated pivotal trial in patients with MASH in the Hepalys Territory, which is planned to start once the results of NATiV3 are available.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.8-4"></a>

### Renal impairment: minor urinary excretion

> “Lanifibranor-related radioactivity elimination was mainly faecal (>85%) and the urinary excretion was minor (<7%) with a very low renal clearance.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-5"></a>

### Renal impairment: effect on kidney function

> “No effect on kidney function or markers of bone turnover was observed.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.8-6"></a>

### Renal impairment: renal function eligibility criteria

> “Serum creatinin < 115 µmol/L (1.3 mg/dL) (men) or < 97 µmol/L (1.1 mg/dL) (women) or estimated glomerular filtration rate ≥ 60 mL/min/1.73m2”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Renal impairment measured as eGFR value < 60 mL/min as determined by Modification of Diet in Renal Disease [MDRD]”
> “In Renal Impairment guidances, FDA and EMA recommend expressing GFR in mL/mn because renal clearance of a drug is proportional to individual GFR and not to BSA-standardized GFR.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-7"></a>

### Renal impairment: dedicated pharmacokinetic study

No evidence found.

<a id="topic-2.1.2.8-8"></a>

### Hepatic impairment: compensated liver disease eligibility criteria

> “Compensated liver disease with the following hematologic and biochemical criteria before randomization:”
> “Platelets > 100 10^9/L (100 10^3/µL)”
> “Albumin > 36 g/L (3.6 g/dL)”
> “INR < 1.4”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-9"></a>

### Hepatic impairment: cirrhosis and abnormal synthetic liver function as exclusion criteria

> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “Abnormal synthetic liver function as defined by Screening central laboratory evaluation”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-10"></a>

### Hepatic impairment: dedicated pharmacokinetic study

No evidence found.

<a id="topic-2.1.2.8-11"></a>

### Autoimmune liver or thyroid disease: exclusion added after a suspected unexpected serious adverse reaction

> “Following the Suspected Unexpected Serious Adverse Reaction”
> “in a patient enrolled in the study, Inventiva chose to voluntarily pause screening and randomization of new patients in the NATiV3 trial to implement the recommendations of the independent Data Monitoring Committee”
> “which included liver monitoring every 6 weeks for each patient enrolled in the trial, and amending the protocol to exclude newly screened patients diagnosed or with a predisposition to autoimmune liver and thyroid disease.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

> “Patients with a personal or close family history of autoimmune liver diseases or a personal history of autoimmune thyroid disease may be at a higher risk for this to occur.”
> “Patients with these conditions will not be eligible to enrol in the study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-12"></a>

### Type 2 diabetes: histologic and glycemic response in participants with diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-2.1.2.8-13"></a>

### Prediabetes: participants without type 2 diabetes

> “Among 144 patients without T2D, 47 (33%) had prediabetes.”
> “With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-2.1.2.8-14"></a>

### Heart failure: exclusion criteria

> “History of heart failure with reduced left ventricular ejection fraction (LVEF)”
> “Unstable heart failure”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the Investigator, would preclude treatment with lanifibranor and/or adequate follow up.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-15"></a>

### Anemia: hemoglobin exclusion threshold

> “Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-16"></a>

### Pregnancy: placental distribution and reproductive toxicity in animals

> “By autoradiography in rat, lanifibranor was shown to be mainly distributed in the excretory organs (liver, kidneys, lungs, gastrointestinal tract) and in placenta in pregnant rats with no affinity for the melanin tissues and with very limited central nervous system penetration.”
> “No potential risks have been identified from pivotal toxicology studies with lanifibranor in rat and in monkey and segment II reproductive toxicity studies in rats and rabbits.”
> “The safety margins over expected human exposure established in segment II reproductive toxicity studies were 9-fold in rats and 2-fold in rabbits (Table 4).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.8-17"></a>

### Pregnancy, breastfeeding, and contraception: trial requirements

> “Pregnancy or lactation or inability to adhere to adequate contraception in women of child-bearing potential.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.”
> “Women currently breastfeeding”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-18"></a>

### Ovulation resumption: listed among important risks of the therapeutic class

> “Clinical experience with medicinal products from the same therapeutic class identified the following important risks:”
> “Ovulation resumption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.8-19"></a>

### Pediatric population: age criterion of 18 years or older

> “Male or female, aged ≥18 years at the time of signing informed consent”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.8-20"></a>

### Pediatric population: pediatric studies

No evidence found.

<a id="topic-2.1.2.8-21"></a>

### Lactose intolerance: lactose monohydrate excipient

> “Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Lactose monohydrate, Hypromellose, Sodium laurilsulfate, Sodium starch glycolate (type A), Magnesium stearate, Opadry™ II 85F18422”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
